Categories
Anticancer Drugs Oncology Pharmacology Physiotherapy Sotorasib

Sotorasib and Specific Populations

In this article we will discuss Sotorasib and Specific Populations

In this article, we will discuss Sotorasib and Specific Populations. So, let’s get started.

Sotorasib and Specific Populations

No clinically meaningful differences in the pharmacokinetics of sotorasib were observed based on age (28 to 86 years), sex, race (White, Black and Asian), body weight (36.8 to 157.9 kg), line of therapy, ECOG PS (0, 1), mild and moderate renal impairment (eGFR: ≥30 mL/min/1.73 m²), or mild hepatic impairment (AST or ALT < 2.5 × ULN or total bilirubin < 1.5 × ULN). The effect of severe renal impairment or moderate to severe hepatic impairment on sotorasib pharmacokinetics has not been studied.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.